Talk:Pneumococcal conjugate vaccine

Evidence supporting addition to routine vaccination schedules

According to one study, doctor visits by those who were diagnosed as having chronic ear infections and who took Prevnar dropped about 20 percent, and there was a similar 20 percent reduction in the number of children who needed tube implants to fight the infections, and overall ear infections were reduced by 9 percent.

For US children under the age of two, the chance of being diagnosed with an invasive pneumococcal disease was determined to be about .15%, or about one chile in 666. Pneumococcal meningitis in childhood has been 'associated with' a mortality rate of approximately 1 in 178,571 children. According to data from the product insert, after one dose of the vaccine .016% of the recipients (3 out of 18,906) were diagnosed with invasive pneumococcal disease; .14% of controls (27 out of 18,910 injected with a different vaccine) got invasive pneumococcal disease. Thus, it was determined Prevnar decreases a child's chance of getting invasive pneumococcal disease by approximately 0.1%.

According to a press release from Wyeth, "...a major clinical trial conducted by Kaiser Permanente.suggested that the vaccine is effective against invasive pneumococcal disease caused by seven serotypes (strains) of the bacteria most prevalent among children in the U.S." According to the Harvard Medical School, the Kaiser study was supported by a grant from Wyeth.

According to the study paid for by Wyeth, "The study showed that children in the vaccine group fared better than those in the comparison group in other ways. In the primary analysis of all acute otitis media episodes (i.e. earaches), children receiving the investigational 7-valent pnemococcal vaccine (i.e. Prevnar) had 7 percent fewer new episodes."

Key Supporters of Prevnar

Key supporters of adding Prevnar to universal vaccination schedules included:

• Dr. Steven Black, Kaiser Permanente
• Dr. Henry Shinefield, Kaiser Permanente
• Dr. Stephen I. Pelton, Boston Medical Center
• Dr. Jerome Klein, Boston Medical Center
• Dr. Margaret B. Rennels, University of Maryland Medical Center
• Dr. Kathryn M. Edwards, Vanderbilt University School of Medicine

Drs. Black and Shinefield undertook most of the studies on Prevnar which proved its efficacy and safety. In promoting the idea of adding four more injections into an already crowded universal US vaccination schedule, Dr. Black asserted, "This vaccine is urgently needed...It is great news for parents and physicians." Dr. Shinefield has said, "It's a remarkable vaccine that will have a dramatic effect." The two Kaiser doctors have spoken at medical conferences throughout the world promoting Prevnar to their colleagues in the medical industry. "

Midgley 18:22, 22 May 2006 (UTC)

merge

I suggest there should be one article on pneumococcal vaccines. Prevnar gets a paragraph in it. Midgley 18:28, 22 May 2006 (UTC)

Proposed move

"Prevnar" should be moved to the generic name of the vaccine: pneumococcal conjugate vaccine. Axl 06:54, 4 September 2007 (UTC)

Agreed; we generally use generic rather than trade names. Without speculating on why this particular article was started under "Prevnar", we ought to move it and leave Prevnar as a redirect, as Axl suggests. MastCell ^Talk 14:49, 4 September 2007 (UTC)

I have moved this page as per the request; please adjust the text as necessary. Dekimasuよ! 14:02, 16 September 2007 (UTC)

Hello- the 1st paragraph should be changed, it uses the commercial name of the 1st conjugate vaccine, however, 10, and 13 valent conjugate vaccines will soon arrive on the market. very important to be balanced and UTD for the credibility of wikipedia. and users of info on this page... —Preceding unsigned comment added by 216.129.222.137 (talk) 16:27, 25 February 2008 (UTC)

Pneumococcal vaccines

I agree with Midgley's suggestion for merging all pneumococcal vaccines related articles. A general article including available informations about all pneumococcal vaccines is more suitable to cover all the problems regarding the pneumoccocal vaccination (including history of pneumococcal vaccination, suitable vaccines to be used at different ages or in different countries, new perspectives in pneumococcal vaccination and so on). RO BlueMonday (talk) 13:53, 1 April 2008 (UTC)

Useful refs?

Can we re-incorporate any of the following refs back into the article and attach them to where they're referenced so they're not dangling? Are these useful refs?

• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen J, Elvin L, Ensor K, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K (2000). "Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group". Pediatr Infect Dis J. 19 (3): 187–95. PMID 10749457. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link) with followup paper:
  Black S, Shinefield H (2002). "Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California". Eur J Pediatr. 161 (Suppl 2): S127–31. doi:10.1007/s00431-002-1064-z. PMID 12494258. {{cite journal}}: Unknown parameter |month= ignored (help)
• Lieu T, Ray G, Black S, Butler J, Klein J, Breiman R, Miller M, Shinefield H (2000). "Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children". JAMA. 283 (11): 1460–8. doi:10.1001/jama.283.11.1460. PMID 10732936. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
• Shinefield H, Black S, Ray P, Chang I, Lewis N, Fireman B, Hackell J, Paradiso P, Siber G, Kohberger R, Madore D, Malinowski F, Kimura A, Le C, Landaw I, Aguilar J, Hansen J (1999). "Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers". Pediatr Infect Dis J. 18 (9): 757–63. doi:10.1097/00006454-199909000-00004. PMID 10493334. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
• Shinefield H, Black S (2000). "Efficacy of pneumococcal conjugate vaccines in large scale field trials". Pediatr Infect Dis J. 19 (4): 394–7. doi:10.1097/00006454-200004000-00036. PMID 10783042. {{cite journal}}: Unknown parameter |month= ignored (help)

Thanks, --InsufficientData (talk) 15:23, 13 January 2009 (UTC)

Effect of PPSV on PCV results

I deleted the sentence, "However, it is more difficult to specifically attribute this decline in adults to the childhood pneumococcal conjugate vaccine since the adult pneumococcal 23-valent polysaccharide vaccine is also available."diff It was unsourced and a probable false implication that PPSV is responsible for a significant part of the decline of adult cases after introduction of PCV. Here's an excerpt from one of the given sources for the sentence that precedes the deleted one.

"The rate of disease caused by serotypes included in the 23-valent polysaccharide vaccine and not in the conjugate vaccine was the same in 2001 as in 1998 and 1999 (11.9 cases per 100,000)."

--Bob K31416 (talk) 02:08, 29 June 2015 (UTC)

External links modified

Hello fellow Wikipedians,

I have just modified 3 external links on Pneumococcal conjugate vaccine. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

• Added archive https://web.archive.org/web/20060615072237/http://www.wyeth.com/content/ShowLabeling.asp?id=134 to http://www.wyeth.com/content/ShowLabeling.asp?id=134
• Added archive https://web.archive.org/web/20100911195649/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm201758.htm to http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm201758.htm
• Added archive https://web.archive.org/web/20071211081606/http://www.rxlist.com/cgi/generic/prevnar.htm to http://www.rxlist.com/cgi/generic/prevnar.htm

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

• If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
• If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 01:19, 19 September 2017 (UTC)

cost controversy

Much media controversy now in 2017 about the high cost, adverse impact on public health budgets in various countries, monopoly patent protections, etc. Please add to article.-73.61.15.24 (talk) 13:32, 8 December 2017 (UTC)

side effects

Please add information about side effects of this vaccine in various populations. And more detailed statistics about benefits. What are the most reputable and comprehensive review studies of benefits vs costs and risks?-73.61.15.24 (talk) 13:37, 8 December 2017 (UTC

I would also like to see a section on side effects. Since this is a "technical" page, I don't have the expertise to include information regarding all the different possible side effects, but I think it is an important thing for this page to have. Side effects can be pronounced, and long lasting (anecdotal, personal experience). Thank you. Bastwren (talk) 10:31, 21 June 2018 (UTC)

Routes of administration?

Routes of administration is set to IM. What is IM? — Preceding unsigned comment added by Tommycarstensen (talk • contribs) 22:05, 7 August 2020 (UTC)

IM stands for intramuscular. Natureium (talk) 02:21, 8 August 2020 (UTC)

Prevnar vs. Prevenar

Is it spelt both ways? If so I suggest the trade/brand name information be updated to show both. Note these two links each use a different spelling: https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13 https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-13 Also, both spellings are used in the source code of the wikipedia page Housecarl (talk) 21:32, 12 May 2021 (UTC)

You are correct. Prevenar in Europe, Prevnar in USA.

The 20-valent Prevnar 20 (USA) is called Apexxnar in Europe.

Why the different names for different countries, has anyone asked Pfizer?

ee1518 (talk) 12:57, 4 December 2022 (UTC)

U.S. adult recommendations

Article focuses too much attention on past recommendations and not enough on current ones. In particular, doesn’t indicate that vaccine is now recommended for almost everyone 50 and older. 47.144.7.66 (talk) 02:22, 6 January 2025 (UTC)

Research section of wikipedia article

Research section is now very empty. Some suggestions, after I Google searched on 7. Nov 2025

adult PCV vaccine trial,

results from 10 first links Google gave me:

1) Adults. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00344-X/fulltext

21-valent PCV21 worked well compared to PCV20 in both cohorts: - Cohort 1 (≥50 years) was stratified by age (50–64, 65–74, 75–84, and ≥85 years). - Cohort 2 (18–49 years).

There were no vaccine-related serious adverse events: 1179 + 200 individuals got PCV21 and 1177+100 individuals got PCV20. So serious adverse events are rare for both vaccines, PCV20 and PCV21.

Funding: Merck.

2) HIV patients. https://pubmed.ncbi.nlm.nih.gov/40953572/

Efficacy of efficiency of PCV21 was studied. Active comparator was PCV15 + PPSV23.

Funding: MSD. MSD is the name used for the American pharmaceutical company Merck & Co., Inc. in all countries outside of the United States and Canada.

3) PCV21 vs PPSV23:

https://www.mdpi.com/2076-393X/13/4/341

And PubPeer comments of the study, nobody has mentioned PPSV23 yet: https://pubpeer.com/publications/3EB0447673A26647543D5E33E75456

4) PCV 21 vs PPSV23:

https://www.sciencedirect.com/science/article/abs/pii/S2666634025001758

Comment) Perhaps PPSV23 was used in the studies because CDC still recommended it on January 9, 2025:

https://www.cdc.gov/mmwr/volumes/74/wr/mm7401a1.htm

Abstract: Options included either 20-valent PCV (PCV20; Prevnar20; Wyeth Pharmaceuticals) or 21-valent PCV (PCV21; CAPVAXIVE; Merck Sharp & Dohme) alone or 15-valent PCV (PCV15; VAXNEUVANCE; Merck Sharp & Dohme) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax23; Merck Sharp & Dohme).

5) Participants were randomized to receive 1 PCV20 or 13-valent PCV (PCV13) dose. After 1 month, All participants aged ≥60 years also received 1 dose of saline or 23-valent polysaccharide vaccine (PPSV23).

https://academic.oup.com/cid/article/75/3/390/6481672

6) https://www.tandfonline.com/doi/full/10.1080/14760584.2024.2404636

Expert opinion: PPV23 was shown to blunt the response to subsequent PCV13.

My question: but does it also blunt if PPV is given after PCV?

---

Then I Googled pcv31, one can not buy this vaccination yet:

1) PCV31 for Adults: At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 Serotypes. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-reports-positive-topline-data-phase-12-study-vax-31-its/

2) https://www.fiercebiotech.com/biotech/vaxcytes-stunning-31-valent-pneumococcal-vaccine-win-against-pfizers-prevnar-20-has

VAX-31, at both the middle and high doses, showed antibody immune responses—as measured by opsonophagocytic activity assay—that either matched or exceeded those of Prevnar 20 for the 20 serotypes shared between the 2 shots.

3) https://vaxcyte.com/pipeline/ VAX-31:

- Adults: Initiate remaining Phase 3 studies in 2026 and announce data from these studies in 2027. - Infants: Announce topline data from the ongoing Phase 2 dose-finding study from both the primary immunization series and booster dose either sequentially or together by the end of first half of 2027.

PCV24:

1) It seems to be intended for infants, as Primary Three-Dose Immunization Series.

https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-announces-positive-topline-results-vax-24-infant-phase-2/

ee1518 (talk) ee1518 (talk) 10:23, 7 November 2025 (UTC)